|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||355.428 g/mol g·mol−1|
|3D model (JSmol)|
Nalmexone (INN) (code names EN-1620A, UM-592), or nalmexone hydrochloride (USAN), is a semisynthetic, opioid partial agonist or mixed agonist-antagonist with both analgesic and narcotic antagonist properties that was never marketed. In clinical studies it was found to have comparable analgesic efficacy to morphine, though with several-fold reduced potency. In addition, nalmexone's side effects, the most common of which were sleepiness and sweating, were reported to be similar to those of morphine, albeit with a noticeably higher degree of incidence.
- Macdonald F (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1395. ISBN 978-0-412-46630-4. Retrieved 11 May 2012.
- Casy AF, Parfitt RT (1986). Opioid Analgesics: Chemistry and Receptors. Springer. p. 55. ISBN 978-0-306-42130-3. Retrieved 11 May 2012.
- Loew GH, Berkowitz DS (1978). "Quantum chemical studies of N-substituent variation in the oxymorphone series of opiate narcotics". Journal of Medicinal Chemistry. 21 (1): 101–106. doi:10.1021/jm00199a018. PMID 73588.
- Forrest WH, Shroff PF, Mahler DL (1972). "Analgesic and other effects of nalmexone in man". Clinical Pharmacology and Therapeutics. 13 (4): 520–525. doi:10.1002/cpt1972134520. PMID 4557582.
- Committee on Problems of Drug Dependence (1969). Bulletin, problems of drug dependence. National Academies. p. 5873. NAP:10503. Retrieved 11 May 2012.
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|